natgillin/translations-raw huggingface dataset:
Da atazanavir og cobicistat i udtalt grad metaboliseres i leveren og er udtalt proteinbundet, er det usandsynligt, at dialyse i signifikant grad kan bidrage til fjernelse af dette lægemiddel. 
Since atazanavir and cobicistat are extensively metabolised by the liver and highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicinal product.
Cobicistat gør dette ved at sænke nedbrydningshastigheden af atazanavir, hvilket vil få atazanavir til at forblive i kroppen i længere tid. 
It does this by slowing down the breakdown of atazanavir which will make it stay in the body for longer.
Anbefalingerne i Tabel 1 er baseret på enten lægemiddelinteraktionsforsøg med ikke-boostet atazanavir, atazanavir boostet med ritonavir, cobicistat eller forventede interaktioner ud fra det forventede omfang af interaktion og mulige bivirkninger eller tab af terapeutisk effekt af EVOTAZ. 
The recommendations shown in Table 1 are based on either drug interaction trials of unboosted atazanavir, atazanavir boosted with ritonavir, cobicistat or predicted interactions due to the expected magnitude of the interaction and potential for serious adverse reactions or loss of therapeutic effect of EVOTAZ.
Atazanavir med cobicistatf (n = 344) 
Atazanavir with cobicistatf (n = 344)
Non-nukleosid reverse transkriptasehæmmere (NNRTI'er) 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Følgende redegørelser vedrører atazanavirs farmakokinetiske egenskaber i kombination med cobicistat eller de enkelte indholdsstoffer i EVOTAZ. 
The following statements reflect the pharmacokinetic properties of atazanavir in combination with cobicistat or the individual components of EVOTAZ.
2% af patienterne behandlet med atazanavir oplevede samtidig grad 3-4 ALAT/ASAT og grad 3-4 forhøjelser af total-bilirubin. 
Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations.
Samtidig anvendelse er kontraindiceret 
Concomitant use contraindicated
Psykiske forstyrrelser almindelig insomni, abnorme drømme ikke almindelig depression, søvnforstyrrelser, desorientering, ængstelse 
Psychiatric disorders common insomnia, abnormal dreams uncommon depression, sleep disorder, disorientation, anxiety
Autoimmune lidelser (såsom Graves sygdom og autoimmun hepatitis) er også rapporteret; tiden til udbrud er imidlertid mere variabel, og udbrud kan optræde mange måneder efter behandlingsstart (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Ved samtidig administration af tenofoviralafenamid/emtricitabin og EVOTAZ er den anbefalede dosis af tenofoviralafenamid/emtricitabin 10/200 mg 1 gang dagligt. 
When co-administering tenofovir alafenamide/emtricitabine and EVOTAZ, the recommended dose of tenofovir alafenamide/emtricitabine is 10/200 mg once daily.
Hvis du føler dig svimmel eller uklar, skal du straks kontakte lægen. 
If you feel dizzy or lightheaded, please contact your doctor immediately.
Atazanavir er blevet undersøgt hos voksne patienter med alvorligt nedsat nyrefunktion (n=20), inklusive patienter i hæmodialyse, ved multiple doser på 400 mg en gang dagligt. 
Atazanavir has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Tenofovir DF kan reducere atazanavirs AUC og Cmin. 
Tenofovir DF may decrease the AUC and Cmin of atazanavir.
Hvis der opstår tegn eller symptomer på nephrolithiasis, kan midlertidig afbrydelse eller seponering af behandlingen overvejes. 
If signs or symptoms of nephrolithiasis occurs, temporary interruption or discontinuation of treatment may be considered.
Hvis EVOTAZ administreres samtidig med irinotecan, bør patienten monitoreres tæt for irinotecan-relaterede bivirkninger. 
If EVOTAZ is co-administered with irinotecan, patients should be closely monitored for adverse reactions related to irinotecan.
HMG-CoA reduktasehæmmere 
HMG-CoA reductase inhibitors
Disse lægemidler er nævnt i starten af afsnit 2 Tag ikke EVOTAZ. 
These are listed under Do not take EVOTAZ, at the start of section 2.
Forhøjede koncentrationer kan forstærke tenofovir-associerede bivirkninger, herunder nyresygdomme. 
Higher concentrations could potentiate tenofovir-associated adverse reactions, including renal disorders.
Samtidig administration af boceprevir og atazanavir/ritonavir medførte lavere atazanavir og ritonavir-eksponering. 
Concomitant administration of boceprevir and atazanavir/ritonavir resulted in reduced exposures to atazanavir and ritonavir.
Tabel 2: Tabel over bivirkninger 
Table 2: Tabulated summary of adverse reactions
PDE5-hæmmere til behandling af erektil dysfunktion 
PDE5 inhibitors used for the treatment of erectile dysfunction
Atazanavir er en svag til moderat CYP2C8-hæmmer. 
Atazanavir is a weak to moderate inhibitor of CYP2C8.
Kortikosteroider, der primært metaboliseres via CYP3A(bl.a. betamethason, budesonid, fluticason, mometason, prednison og triamcinolon). 
Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
Der bør ligeledes udvises forsigtighed, hvis der under den første behandling skiftes farmakoforstærker fra ritonavir til cobicistat (se pkt. 
Caution is also required during the first time of treatment if switching the pharmacoenhancer from ritonavir to cobicistat (see section 4.4).
Forhøjede plasmakoncentrationer af lægemidler, der metaboliseres af CYP3A, CYP2C8, CYP2D6 og/eller UGT1A1 forventes ved samtidig administration med EVOTAZ. 
Increased plasma concentrations of medicinal products that are metabolised by CYP3A, CYP2C8, CYP2D6 and/or UGT1A1 are expected when co-administered with EVOTAZ.
Atazanavir med ritonavirf (n = 348) 
Atazanavir with ritonavirf (n = 348)
Ved samtidig administration med EVOTAZ bør digoxin-dosis titreres og digoxin-koncentrationen bør monitoreres. 
When co-administering with EVOTAZ, titrate the digoxin dose and monitor digoxin concentrations.
Median CD4+ celletal ved baseline var 352 celler/mm3 (1-1.455) og 16,9% havde CD4+ 
The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3.
Sikkerheden og virkningen af atazanavir med cobicistat hos hiv-1 inficerede patienter blev evalueret i et randomiseret, dobbeltblindet, aktivt-kontrolleret fase 3 studie GS-US-216-0114 hos hiv-1-inficerede patienter med estimeret kreatininclearance ved baseline over 70 ml/min, som var behandlingsnaive (n = 692). 
The safety and efficacy of atazanavir with cobicistat in HIV-1 infected patients were evaluated in the randomised, double-blind, active-controlled phase 3 study GS-US-216-0114 in HIV-1 infected patients with baseline estimated creatinine clearance above 70 ml/min who were treatment-naïve (n = 692).
Patienterne bør advares om risikoen for disse bivirkninger ved brug af PDE5-hæmmere mod erektil dysfunktion samtidig med EVOTAZ (se pkt. 
Patients should be warned about these possible side effects when using PDE5 inhibitors for erectile dysfunction with EVOTAZ (see section 4.4).
EVOTAZ 300 mg/150 mg filmovertrukne tabletter atazanavir/cobicistat 
EVOTAZ 300 mg/150 mg film-coated tablets atazanavir/cobicistat
Amiodaron, dronedaron, quinidin og systemisk lidocain har et snævert terapeutisk indeks og er kontraindiceret pga. EVOTAZ's potentielle CYP3A-hæmning (se pkt. 
Amiodarone, dronedarone, quinidine and systemic lidocaine have a narrow therapeutic window and are contraindicated due to potential inhibition of CYP3A by EVOTAZ (see section 4.3).
I et ex vivo farmakologistudie i kaniner blev isolerede hjerter eksponeret for atazanavir, cobicistat eller en kombination af disse to. 
In an ex vivo rabbit pharmacology study, isolated hearts were exposed to atazanavir, cobicistat, or atazanavir and cobicistat in combination.
Maraviroc er et CYP3A-substrat og dets plasmakoncentration øges ved samtidig administration med potente CYP3A-hæmmere. 
Maraviroc is a substrate of CYP3A and its plasma concentration increases when co-administered with potent CYP3A inhibitors.
Der er begrænset erfaring med akut human overdosering med EVOTAZ. 
Human experience of acute overdose with EVOTAZ is limited.
Metabolisme og ernæring almindelig øget appetit ikke almindelig vægttab, vægtstigning, anoreksi 
Metabolism and nutrition disorders common increased appetite uncommon weight decreased, weight gain, anorexia
Regelmæssig overvågning af patienternes nyrefunktion bør opretholdes igennem hele behandlingsforløbet (se pkt. 
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.4)
Ethinylestradiol AUC: ↔ Ethinylestradiol Cmax: ↔ Ethinylestradiol Cmin: Ikke beregnet 
Ethinyloestradiol AUC: ↔ Ethinyloestradiol Cmax: ↔ Ethinyloestradiol Cmin: Not calculated
Der foreligger kun begrænsede data om udvikling af resistens over for atazanavir boostet med cobicistat. 
Limited data are available on the development of resistance to atazanavir boosted with cobicistat.
EVOTAZ er indiceret i kombination med andre antiretrovirale lægemidler til behandling af hiv-1inficerede voksne uden kendte mutationer associeret med resistens over for atazanavir (se pkt. 
EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).
Andre markante, kliniske laboratoriemæssige anormaliteter (grad 3 eller 4) rapporteret hos ≥2% af patienterne, der fik regimer indeholdende atazanavir og én eller flere NRTIer omfattede: forhøjet kreatinkinase (7%), forhøjet alaninaminotransferase/serum-glutamin-pyrudrue transaminase (ALAT/SGPT) (5%), lav neutrofiltælling (5%), forhøjet aspartataminotransferase/serumglutamin-oxalsyretransaminase (ASAT/SGOT) (3%) og forhøjet lipase (3%). 
Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2% of patients receiving regimens containing atazanavir and one or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%).
Samtidig administration af EVOTAZ hos patienter, der får lægemidler som er substrater af transportproteinerne P-gp, BCRP, MATE1, OATP1B1 og OATP1B3 kan resultere i forhøjede plasmakoncentrationer af de samtidigt administrerede lægemidler (se pkt. 
Co-administration of EVOTAZ in patients receiving medicinal products that are substrates of the transporters P-gp, BCRP, MATE1, OATP1B1 and OATP1B3 may result in increased plasma concentrations of the co-administered medicinal products (see section 4.4).
Et farmakokinetikstudie af cobicistat blev udført hos ikke-hiv-1-inficerede personer med svært nedsat nyrefunktion (estimeret kreatininclearance under 30 ml/min). 
A study of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 ml/min).
Hos hiv-inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af antiretroviral kombinationsbehandling (CART) opstå inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske infektioner. 
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
f. Plus baggrundsbehandlingsplan med emtricitabin 200 mg og tenofovir DF 300 mg i fastdosiskombination. 
f Plus background regimen of emtricitabine 200 mg and tenofovir DF 300 mg fixed-dose combination.
Samtidig administration af EVOTAZ og tenofoviralafenamid 25 mg til behandling af HBVinfektion frarådes 
Co-administration of EVOTAZ and tenofovir alafenamide 25 mg for treatment of HBV infection is not recommended
EVOTAZ's antiretrovirale effekt skyldes indholdsstoffet atazanavir. 
The antiretroviral effect of EVOTAZ is due to the atazanavir component.
Pink, oval, bikonveks, filmovertrukket tablet med omtrentlig dimension på 19 mm x 10,4 mm og præget med ”3641” på den ene side og glat på den anden side. 
Pink, oval, biconvex, film-coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed with "3641" on one side and plain on the other side.
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 30 filmovertrukne tabletter. 
PHARMACEUTICAL FORM AND CONTENTS 30 film-coated tablets.
Der er rapporteret alvorligt hududslæt, herunder Stevens-Johnsons syndrom, hos patienter, der tager EVOTAZ. 
Serious skin rash, including Stevens-Johnson syndrome, may develop in patients taking EVOTAZ.
Hvis du bemærker et eller flere af disse symptomer, skal du fortælle det til lægen. 
If you notice any of these symptoms please inform your doctor.
Atazanavir-koncentrationen påvirkes ikke signifikant. 
Concentrations of atazanavir were not significantly affected.
Atazanavir + cobicistat + emtricitabin og tenofovir DF i fastdosiskombination var non-inferiøre med hensyn til at opnå hiv-1-RNA <50 kopier/ml, sammenlignet med atazanavir + ritonavir + emtricitabin og tenofovir DF i fastdosiskombination. 
Atazanavir with cobicistat and emtricitabine and tenofovir DF fixed-dose combination was non-inferior in achieving HIV-1 RNA <50 copies/ml when compared to atazanavir with ritonavir and emtricitabine and tenofovir DF fixed-dose combination.
Immunreaktiveringssyndrom og autoimmune lidelser 
Immune reactivation syndrome and autoimmune disorders
Nukleosid/nukleotid reverse transkriptasehæmmere (NRTI'er) 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
En opdateret RMP skal fremsendes: på anmodning fra Det Europæiske Lægemiddelagentur når risikostyringssystemet ændres, særlig som følge af, at der er modtaget nye oplysninger, der kan medføre en væsentlig ændring i benefit/risk-forholdet, eller som følge af, at en vigtig milepæl (lægemiddelovervågning eller risikominimering) er nået. 
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Samtidig administration af EVOTAZ kan potentielt medføre alvorlige og/eller livstruende bivirkninger. 
Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions.
Selvom det ikke er undersøgt, er der risiko for en øget pravastatineller fluvastatin-eksponering ved administration sammen med proteasehæmmere. 
Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when co-administered with protease inhibitors.
Samtidig administration af EVOTAZ og ticagrelor kan øge koncentrationen af antikoagulanten. 
Co- administration of EVOTAZ and ticagrelor may increase concentrations of the anticoagulant.
Administration af en enkeltdosis EVOTAZ med et fedtrigt måltid (1.038 kcal, 59 g fedt, 37 g protein) medførte en 14% reduktion i atazanavir Cmax men ingen ændringer i atazanavir AUC eller cobicistat-eksponering (Cmax, AUC) i forhold til fastende tilstand. 
Administration of a single dose of EVOTAZ with a high fat meal (1,038 kcal, 59 g fat, 37 g protein) resulted in a 14% reduction in atazanavir Cmax with no change in atazanavir AUC or cobicistat exposures (Cmax, AUC) relative to the fasting state.
Cobicistats hæmning af CYP3A-medieret metabolisme øger den systemiske eksponering over for CYP3A-substrater, såsom atazanavir, som har begrænset biotilgængelighed og en kort halveringstid på grund af den CYP3A-afhængige metabolisme. 
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism.
Forsigtighed anbefales. 
Caution is warranted.
Klinisk monitorering og laboratoriemonitorering for hyperbilirubinæmi anbefales. 
Clinical and laboratory monitoring for hyperbilirubinaemia is recommended.
Forsøgspersoner, der udviste signifikante anormaliteter i leverfunktionstests, havde generelt abnorme baseline transaminase-værdier (ASAT eller ALAT), underliggende kronisk eller akut hepatitis B eller -C-infektion, fik samtidig hepatotoksiske lægemidler (f.eks. isoniazid) eller havde alkoholisme eller alkoholmisbrug i anamnesen. 
Subjects with significant liver function test abnormalities generally had abnormal baseline transaminases (AST or ALT), underlying chronic or acute hepatitis B or C co-infection, concomitant hepatotoxic medications (e.g., isoniazid), or a medical history of alcoholism or alcohol abuse.
EVOTAZ er en fastdosiskombination af det antivirale lægemiddel atazanavir boostet med den farmakokinetiske forstærker cobicistat. 
EVOTAZ is a fixed-dose combination of the antiviral drug atazanavir boosted by the pharmacokinetic enhancer cobicistat.
Samtidig administration af neuroleptika og EVOTAZ kan medføre øgede plasmakoncentrationer af neuroleptika. 
Co-administration of neuroleptics with EVOTAZ may result in increased plasma concentrations of neuroleptics.
Brug af anden medicin sammen med EVOTAZ 
Other medicines and EVOTAZ
Samtidig administration af EVOTAZ og ticagrelor er kontraindiceret. 
Concomitant administration of EVOTAZ with ticagrelor is contraindicated.
EVOTAZ frarådes til samtidig administration med efavirenz. 
EVOTAZ is not recommended for co-administration with efavirenz.
Anvendelse af EVOTAZ er kontraindiceret hos patienter med moderat til svært nedsat leverfunktion. 
The use of EVOTAZ is contraindicated in patients with moderate to severe hepatic impairment.
Moderat til svært nedsat leverfunktion. 
Moderate to severe hepatic impairment.
Hvert enkelt lægemiddelstof påvirkede venstre ventrikulær kontraktilitet og PR-forlængelse ved koncentrationer mindst 35 gange højere end frie atazanavir- og cobicistat-koncentrationer ved den anbefalede humane dosis (RHD) Cmax. 
Each single agent produced effects on left ventricular contractility and PR prolongation at concentrations at least 35-fold higher than the free atazanavir and cobicistat concentrations at the recommended human dose (RHD) Cmax.
Virologisk svigtc 
Virologic success
Der er observeret øgede plasmakoncentrationer af lægemidler, som metaboliseres af CYP3A (herunder atazanavir) ved samtidig administration af cobicistat. 
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir) are observed on co-administration with cobicistat.
Simvastatin og lovastatin metaboliseres i høj grad via CYP3A4 og samtidig administration med EVOTAZ kan medføre øgede koncentrationer. 
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with EVOTAZ may result in increased concentrations.
Kortikosteroider, som er mindre afhængige af CYP3Ametabolisering, f.eks. nasal eller inhaleret beclometason, bør overvejes, navnlig ved langvarig brug. 
Alternative corticosteroids which are less dependent on CYP3A metabolism, e.g. beclomethasone for intranasal or inhalational use, should be considered, particularly for long term use.
Kombinationen af pimozid, quetiapin eller lurasidon og EVOTAZ er kontraindiceret (se pkt. 
The combination of pimozide, quetiapine or lurasidone and EVOTAZ is contraindicated (see section 4.3).
Atazanavir, doseret 1 time efter ddI+d4T (fastende) Atazanavir AUC ↔3% (↓36% 
Atazanavir, dosed 1 hr after ddI+d4T (fasted) Atazanavir AUC ↔3% (↓36%
Der bør udvises forsigtighed, og monitorering af terapeutiske koncentrationer for disse lægemidler anbefales ved samtidig anvendelse med EVOTAZ. 
Caution is warranted and therapeutic concentration monitoring of these medicinal products is recommended if they are used concomitantly with EVOTAZ.
Rifabutin AUC ↑48% (↑19% Rifabutin Cmax ↑149% (↑103% Rifabutin Cmin ↑40% (↑5% ↑87%)* 25-O-desacetyl-rifabutin AUC 25-O-desacetyl-rifabutin Cmax 25-O-desacetyl-rifabutin Cmin *Sammenlignet med rifabutin 150 mg 1 gang dagligt. 
Rifabutin AUC ↑48% (↑19% Rifabutin Cmax ↑149% (↑103% Rifabutin Cmin ↑40% (↑5% 25-O-desacetyl-rifabutin AUC 25-O-desacetyl-rifabutin Cmax 25-O-desacetyl-rifabutin Cmin *When compared to rifabutin 150 mg once daily alone.
Dosisnedsættelse af neuroleptika, som metaboliseres af CYP3A eller CYP2D6, kan være nødvendig ved samtidig administration med EVOTAZ. 
A decrease in the dose of neuroleptics metabolized by CYP3A or CYP2D6 may be required when co-administered with EVOTAZ.
Blandt de 19 patienter udviklede 1 den emtricitabine-relaterede resistenssubstitution M184V uden nogen resistenssubstitioner associeret med tenofovir eller proteasehæmmere. 
Among the 19 patients, 1 developed the emtricitabine-associated resistance substitution M184V with no tenofovir or protease inhibitor associated resistance substitutions.
Sammenlignet med profilen for det enkelte lægemiddelstof kunne alle fund tilskrives enten atazanavir eller cobicistat. 
When compared to their single-agent profiles all findings could be attributed to either atazanavir or cobicistat.
Samtidig administration med EVOTAZ kan øge plasmakoncentrationerne af lægemidler, der metaboliseres af CYP2D6 (se pkt. 
Co-administration with EVOTAZ can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
I et forsøg, hvor hiv-inficerede forsøgspersoner (n=22) blev instrueret i at tage atazanavir 300 mg med cobicistat 150 mg 1 gang dagligt med føde, var steady-state atazanavir Cmax, AUCtau and Ctau (gennemsnitlig ± SD) værdierne henholdsvis 3,9 ± 1,9 μg/ml, 46,1 ± 26,2 μg•hr/ml og 0,80 ± 0,72 μg/ml. 
In a trial where HIV-infected subjects (n=22) were instructed to take atazanavir 300 mg with cobicistat 150 mg once daily with food, the steady-state atazanavir Cmax, AUCtau and Ctau (mean ± SD) values were 3.9 ± 1.9 μg/ml, 46.1 ± 26.2 μg•hr/ml and 0.80 ± 0.72 μg/ml, respectively.
Administration af en enkeltdosis EVOTAZ med et let måltid (336 kcal, 5,1 g fedt, 9,3 g protein) medførte en 42% stigning i atazanavir Cmax, en 28% stigning i atazanavir AUC, en 31% stigning i cobicistat Cmax og en 24% stigning i cobicistat AUC i forhold til fastende tilstand. 
Administration of a single dose of EVOTAZ with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 42% increase in atazanavir Cmax, a 28% increase in atazanavir AUC, a 31% increase in cobicistat Cmax, and a 24% increase in cobicistat AUC relative to the fasting state.
I en analyse af behandlingsnaive forsøgspersoner, som fik atazanavir 300 mg administreret sammen med cobicistat 150 mg i studie GS-US-216-0114 i uge 144, forelå der evaluerbare genotypiske data fra parvise baseline- og behandlingssvigt-isolater for alle 21 virologiske svigt i denne gruppe (6%, 21/344). 
In an analysis of treatment-failure subjects who received atazanavir 300 mg co-administered with cobicistat 150 mg in study GS-US-216-0114 through Week 144, evaluable genotypic data from paired baseline and treatment-failure isolates were available for all 21 virologic failures in this group (6%, 21/344).
I det kliniske studie GS-US-216-0114, et fase 3 randomiseret, aktivt kontrolleret klinisk studie, hvor 692 behandlingsnaive patienter fik mindst en dosis atazanavir boostet med cobicistat (n = 344) eller atazanavir boostet med ritonavir (n = 348) administreret med andre antiretrovirale lægemidler, var de hyppigst rapporterede bivirkninger i gruppen med atazanavir boostet med cobicistat i et forløb på 144 uger associeret med forhøjede bilirubin-niveauer (se Tabel 2). 
In clinical study GS-US-216-0114, a phase 3 randomised, active-controlled clinical study, in which 692 treatment-naïve patients received at least one dose of atazanavir boosted with cobicistat (n = 344) or atazanavir boosted with ritonavir (n = 348) administered with other antiretroviral medicinal products, the most frequently reported adverse reactions in the atazanavir boosted with cobicistat group during 144 weeks were associated with elevated bilirubin levels (see Table 2).